Clinical Trial Finder

• Restore CFTR FunctionEnrolling

  Phase 3 study of ivacaftor in babies who have a CFTR gating mutation , protocol number Vertex VX15-770-124

  This two-part, open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of ivacaftor, as well as how the body processes the drug, in babies who have a CFTR gating mutation.

  • Age:

    0 Months to 12 Months

  • Mutation(s):

    One Copy F508del or No Copies F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    8

  • Length of Participation:

    24 weeks

• Mucociliary ClearanceEnrolling

  BALANCE-CF 1: Study of BI 1265162, a mucus clearance drug, in teens and adults with CF , protocol number BI 1399-0003

  This study will look at the safety and effectiveness of BI 1265162, a drug intended to improve the clearance of mucus from the lungs. This study is for people with CF ages 12 and older.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    5

  • Length of Participation:

    7 weeks

• Anti-InflammatoryEnrolling

  Phase 2 study of LAU-7b in adults with CF (APPLAUD) , protocol number Laurent LAU-14-01

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and will use a placebo control.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    6

  • Length of Participation:

    189 days

• Anti-InfectiveEnrolling

  Phase 2 study of inhaled nitric oxide in people with CF , protocol number Novoteris NO-CF-02E

  This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug nitric oxide in adults with cystic fibrosis who are taking an inhaled antibiotic.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    35 to 85%

  • Number of Visits:

    10

  • Length of Participation:

    43 days

• ObservationalEnrolling

  Rare mutation cell collection (RARE) , protocol number RARE-OB-16

  This study is taking place at six regional care centers across the U.S. Researchers will collect and make available for study cells from people with rare CFTR mutations.

  • Age:

    12 Years and Older

  • Mutation(s):

    One Copy F508del or No Copies F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    1

  • Length of Participation:

    2 days

• OtherEnrolling

  Study of SPI-1005 in people with CF ages 18 and older , protocol number Sound Pharma SPI-3005-501.2

  This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    6

  • Length of Participation:

    49 days

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.